These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 6124402)

  • 81. Use of stable isotopes in the study of pharmacokinetics of drugs by mass fragmentography II: Detailed examination of pharmacokinetics of a single oral dose of phenytoin in humans.
    Baba S; Goromaru T; Yamazaki K; Kasuya Y
    J Pharm Sci; 1980 Nov; 69(11):1300-7. PubMed ID: 7452459
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparative drug elimination in man-diphenylhydantoin and amobarbital.
    Brien JF; Inaba T; Kalow W
    Eur J Clin Pharmacol; 1975 Oct; 9(1):79-83. PubMed ID: 1233257
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Absorption and metabolism of phenytoin from tablets and capsules.
    Smith TC; Kinkel A
    Clin Pharmacol Ther; 1976 Dec; 20(6):738-42. PubMed ID: 791565
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Enhancement of diphenylhydantoin binding by lipid extraction.
    Goldberg MA; Todoroff T
    J Pharmacol Exp Ther; 1976 Mar; 196(3):579-85. PubMed ID: 1263113
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Folic acid and the protective action of diphenylhydantoin against maximal electroshock in rats after single doses.
    van Rees H; Telkers-Duijts GA; Noach EL
    Arch Int Pharmacodyn Ther; 1983 Jan; 261(1):16-22. PubMed ID: 6847314
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Phenytoin metabolism in subjects with long and short plasma half-lives.
    Glazko AJ; Peterson FE; Chang T; Dill WA; Smith TC; Buchanan RA
    Ther Drug Monit; 1982; 4(3):281-92. PubMed ID: 7135458
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Phenytoin metabolism in infants following intravenous and oral administration.
    Leff RD; Fischer LJ; Roberts RJ
    Dev Pharmacol Ther; 1986; 9(4):217-23. PubMed ID: 3757729
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Drug interaction between phenytoin and allopurinol.
    Ogiso T; Ito Y; Iwaki M; Tsunekawa K
    J Pharmacobiodyn; 1990 Jan; 13(1):36-43. PubMed ID: 2341968
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria.
    Takahashi A; Onodera K; Shinoda H; Mayanagi H
    Jpn J Pharmacol; 2000 Jan; 82(1):82-4. PubMed ID: 10874595
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Influences on the absorption of diphenylhydantoin preparations.
    Windorfer A; Stünkel S; Weimann HM
    Neuropadiatrie; 1978 May; 9(2):120-6. PubMed ID: 581216
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A model describing the disposition of phenytoin in isolated rat hepatocytes.
    Morais JA; Wagner JG
    Biopharm Drug Dispos; 1984; 5(4):357-76. PubMed ID: 6525443
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Direct high-performance liquid chromatographic analysis of p-hydroxyphenyl-phenylhydantoin glucuronide, the final metabolite of phenytoin, in human serum and urine.
    Vree TB; Steegers-Theunissen RP; Baars AM; Hekster YA
    J Chromatogr; 1990 Apr; 526(2):581-9. PubMed ID: 2362000
    [No Abstract]   [Full Text] [Related]  

  • 93. Phenytoin: pharmacogenetic polymorphism of 4'-hydroxylation.
    Inaba T
    Pharmacol Ther; 1990; 46(3):341-7. PubMed ID: 2188267
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Rate of elimination of tracer doses of phenytoin at different steady-state serum phenytoin concentrations in epileptic patients.
    Houghton GW; Richens A
    Br J Clin Pharmacol; 1974 Apr; 1(2):155-61. PubMed ID: 22454903
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The influence of folic acid on phenytoin (DPH) metabolism and the 24-hours fluctuation in urinary output of 5-(p-hydroxyphenyl)-5 phenyl-hydantoin (HPPH).
    Olesen OV; Jensen ON
    Acta Pharmacol Toxicol (Copenh); 1970; 28(4):265-9. PubMed ID: 5536016
    [No Abstract]   [Full Text] [Related]  

  • 96. Identification of urinary catechol and methylated catechol metabolites of phenytoin in humans, monkeys, and dogs by GLC and GLC-mass spectrometry.
    Midha KK; Hindmarsh KW; McGilveray IJ; Cooper JK
    J Pharm Sci; 1977 Nov; 66(11):1596-602. PubMed ID: 410919
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The intestinal dialysis of intravenously administered phenytoin by oral activated charcoal in rats.
    Arimori K; Nakano M
    J Pharmacobiodyn; 1987 Apr; 10(4):157-65. PubMed ID: 3656062
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin.
    Dickinson RG; Hooper WD; Patterson M; Eadie MJ; Maguire B
    Ther Drug Monit; 1985; 7(3):283-9. PubMed ID: 4049465
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A complex pattern of disposition of phenytoin in severe intoxication.
    Pruitt AW; Zwiren GT; Patterson JH; Dayton PG; Cook CE; Wall ME
    Clin Pharmacol Ther; 1975 Jul; 18(1):112-20. PubMed ID: 238781
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Spectroscopic determination of the major metabolite of phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin in human urine.
    Moustafa MA; Belal F; el-Emam AA
    J Pharm Belg; 1987; 42(1):53-8. PubMed ID: 3585688
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.